This proof-of-principle study, demonstrating that IGF2 modulation overcomes multiple Taxol resistance mechanisms, now forms the basis for preclinical testing of IGF2 targeting agents in combination with standard combination ovarian cancer treatment regimens. This evidence concerns the gene IGF2 and ovarian carcinoma.